Non–chemotherapy drug–induced neutropenia: key points to manage the challenges
- 8 December 2017
- journal article
- research article
- Published by American Society of Hematology in Hematology
- Vol. 2017 (1), 187-193
- https://doi.org/10.1182/asheducation-2017.1.187
Abstract
Non–chemotherapy idiosyncratic drug–induced neutropenia (IDIN) is a relatively rare but potentially fatal disorder that occurs in susceptible individuals, with an incidence of 2.4 to 15.4 cases per million population. Affected patients typically experience severe neutropenia within several weeks to several months after first exposure to a drug, and mortality is ∼5%. The drugs most frequently associated with IDIN include metamizole, clozapine, sulfasalazine, thiamazole, carbimazole, amoxicillin, cotrimoxazole, ticlopidine, and valganciclovir. The idiosyncratic nature of IDIN, the lack of mouse models and diagnostic testing, and its low overall incidence make rigorous studies to elucidate possible mechanisms exceptionally difficult. An immune mechanism for IDIN involving neutrophil destruction by hapten (drug)-specific antibodies and drug-induced autoantibodies is frequently suggested, but strong supporting evidence is lacking. Although laboratory testing for neutrophil drug-dependent antibodies is rarely performed because of the complexity and low sensitivity of tests currently in use, these assays could possibly be enhanced by using reactive drug metabolites in place of the parent drug. Patients typically experience acute, severe neutropenia, or agranulocytosis (<0.5 × 109 neutrophils/L) and symptoms of fever, chills, sore throat, and muscle and joint pain. Diagnosis can be difficult, but timely recognition is critical because if left untreated, there is an increase in mortality. Expanded studies of the production and mechanistic role of reactive drug metabolites, genetic associations, and improved animal models of IDIN are essential to further our understanding of this important disorder.This publication has 63 references indexed in Scilit:
- The role of haematopoietic growth factors granulocyte colony‐stimulating factor and granulocyte‐macrophage colony‐stimulating factor in the management of drug‐induced agranulocytosisBritish Journal of Haematology, 2010
- Clinicopathologic Features of Agranulocytosis in the Setting of Levamisole-Tainted CocaineAmerican Journal of Clinical Pathology, 2010
- Idiosyncratic drug‐induced agranulocytosis: Possible mechanisms and managementAmerican Journal of Hematology, 2009
- Drug-Induced Immune ThrombocytopeniaThe New England Journal of Medicine, 2007
- New Concepts in Immunology Relevant to Idiosyncratic Drug Reactions: The “Danger Hypothesis” and Innate Immune SystemChemical Research in Toxicology, 1999
- Granulocyte Colony-Stimulating Factor (G-CSF) Does Not Improve Recovery from Antithyroid Drug-Induced Agranulocytosis: A Prospective StudyThyroid®, 1999
- The chemical and immunoglobulin structural features necessary for reactions of quinine‐dependent antibodies to neutrophilsTransfusion, 1995
- Analysis of granulocyte‐reactive antibodies using an immunoassay based upon monoclonal‐antibody‐specific immobilization of granulocyte antigensTransfusion Medicine, 1993
- Immune‐mediated agranulocytosis related to drugs and their metabolites: mode of sensitization and heterogeneity of antibodiesBritish Journal of Haematology, 1989
- Agranulocytosis induced by propylthiouracil: evidence of a drug dependent antibody reacting with granulocytes, monocytes and haematopoietic progenitor cellsBritish Journal of Haematology, 1986